Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease _ Bacteriology_Antibiotics

Synereca Pharmaceuticals

Parents

2011: UNC spinout raises $300K to build a better antibiotic (2011)
A prototype of this enzyme inhibitor showed that blocking the bacterial repair abilities of the enzyme improves the effects of antibiotics such as flouroquinolone and penicillin.
Based on the scientific research of Scott Singleton, the company’s president and chief scientific officer, and a professor of medicinal chemistry and natural products at UNC’s Eshelman School of Pharmacy.
The company is developing compounds that inhibit the bacterial enzyme RecA.
This enzyme is a key factor in bacterial DNA repair and the development of antibiotic resistance.